PABPC3 and ovarian carcinoma: To investigate the impact of PABPC3 on drug sensitivity, we treated ID8 and Flag-PABPC3 cell lines with the common first-line chemotherapeutic agents, including carboplatin [30] and paclitaxel [31, 32], as well as the PARP inhibitor Olaparib [33, 34], which has been increasingly used to treat ovarian cancer.